Not a cholesterol drug.
Statins don't just lower cholesterol. They block HMG-CoA reductase — the upstream gateway of the mevalonate pathway — which produces CoQ10, vitamin K2, steroid hormones, vitamin D precursors, and the signaling molecules your cells need to function. Calling them “cholesterol drugs” hides what they actually do.
The distinction that changes everything
When you call a drug a “cholesterol drug,” the implied logic is that the only meaningful effect is the one on your lipid panel. The muscle pain, the fatigue, the blood sugar creeping up, the joints that ache — all treated as coincidental. When you understand that the drug is a mevalonate pathway inhibitor, a different question emerges: what else does this pathway produce, and what happens when those outputs are chronically suppressed?
People must take a statin 5 years for 1 to avoid a nonfatal heart attack (primary prevention)
Increased odds of severe coronary calcification after 10+ years of statin use
CoQ10 depletion documented in statin users — powering the heart you're trying to protect
What else the mevalonate pathway makes.
Cholesterol is one output. Here's what else gets suppressed when you block the pathway at the top.
Mitochondrial energy production
The electron shuttle your mitochondria need to make ATP. Depleted 16–49% by statins. The heart is the most energy-demanding muscle in your body, and we're depleting its fuel source to “protect” it.
Vascular calcium regulation
K2 activates the protein (MGP) that keeps calcium out of your arteries and puts it in your bones. Statins reduce the precursor needed to make K2. The result? A drug prescribed to protect arteries is associated with a dose-dependent increase in coronary calcification.
Every steroid hormone in your body
Cholesterol is the structural precursor for testosterone, estrogen, progesterone, cortisol, DHEA, aldosterone, and vitamin D. Reducing cholesterol synthesis reduces the raw material for all of them. Multiple meta-analyses confirm statins lower testosterone.
Cellular signaling molecules
Prenyl groups required for Ras, Rho, Rac, and Rab proteins to function — governing cell proliferation, immune activation, and glucose transport. The same suppression that produces the “anti-inflammatory benefits” also breaks GLUT-4 trafficking, directly causing insulin resistance.
The drug calcifies the arteries it's supposed to protect.
This is documented. It's dose-dependent. And it gets worse over time.
Severe calcification odds after 0–5 years
After 5–10 years
After 10+ years
The K2 connection
Statins reduce the precursor (GGPP) that your body needs to synthesize vitamin K2. K2 activates the most potent known inhibitor of vascular calcification (Matrix Gla Protein). Without K2, calcium accumulates in your arteries instead of your bones. Animal studies show 45% reductions in tissue K2 from atorvastatin. Clinical studies show statin users have elevated markers of K deficiency that correlate with coronary calcium scores.
The official response
Cardiologists say the calcification may represent “denser, more stable deposits” that reduce plaque rupture risk. Maybe. But a fivefold increase in severe coronary calcification with long-term use of a drug prescribed to protect coronary arteries is not something that should be quietly filed under “paradox.”
What they tell you vs. what the numbers actually say.
“Statins reduce heart attacks by 30%.” That's a relative risk reduction. Here are the absolute numbers — the ones that rarely appear in the same sentence as the prescription.
NNT 217 for nonfatal heart attack (primary prevention)
217 people take the drug for 5 years. 216 experience whatever side effects they experience and receive no benefit. The 217th avoids a nonfatal heart attack.
NNT 313 for stroke prevention
313 people, 5 years of daily medication, for one stroke prevented. The other 312 got the side effects and no benefit.
No mortality benefit in primary prevention
In patients without established heart disease, there is no statistically significant overall mortality benefit from statin therapy. The drugs reduce some nonfatal events in a modest minority while producing side effects in a substantial minority. These two facts rarely appear in the same sentence when a prescription is written.
Who actually benefits?
For patients who have already had a cardiovascular event (secondary prevention), the absolute benefit is more meaningful and the calculus is different. We don't dismiss that evidence. But most statin prescriptions are written in primary prevention — for people who have not had a heart attack — where the NNTs are enormous and the side effects are real.
A drug for heart disease that causes diabetes.
The FDA added the diabetes warning in 2012 — after decades of widespread use.
This is the mechanism, not a side effect
Statins reduce GLUT-4 expression (the glucose transporter), impair insulin secretion in the pancreas, activate liver gluconeogenesis, and break the prenylation required for glucose transport. Mendelian randomization studies show that genetic variants that do the same thing statins do — reduce HMG-CoA reductase activity — also increase diabetes risk. The diabetogenic effect isn't a drug side effect. It's the core mechanism.
The circular problem
A drug prescribed to reduce cardiovascular risk causes a condition (diabetes) that itself increases cardiovascular risk. For high-risk patients with established disease, the trade-off may be worth it. For low-risk patients prescribed statins based on a number, who now develop diabetes, the math doesn't work.
The brain runs on cholesterol.
20% of the body's cholesterol, 2% of its mass
The brain synthesizes its own cholesterol locally. It's essential for myelin, synaptic function, neurotransmitter receptors, and membrane integrity. Lipophilic statins (simvastatin, atorvastatin) cross the blood-brain barrier and suppress this local production. Hydrophilic statins don't. That distinction is rarely discussed when the prescription is written.
FDA warning: memory loss, confusion, amnesia
Added in 2012. A UK Biobank study of 147,000+ people found reduced LDL may be detrimental to cognition, with LDL mediating more than 50% of the association between statin use and cognitive decline. Both very high and very low LDL are associated with worse outcomes — a U-shaped curve.
The funding gap in side effect reporting
Industry-funded trials report muscle symptoms below 1%. Non-industry trials report 10–25%. Some observational studies: 60%. Treatment guidelines are built predominantly on industry-sponsored evidence. A patient taking a drug every day for decades deserves to know that the side effect rates in guideline-forming studies may not reflect their actual experience.
Rename the drug. Change the questions.
The mevalonate pathway is a hub, not a pipeline. Blocking it at the top doesn't selectively lower one number on a panel. It reduces substrate for energy production, calcium regulation, hormone synthesis, protein folding, and cellular signaling. We have been focused on one number while dozens of downstream effects have accumulated in patients who were told they were taking a simple cholesterol drug.
Calling it a mevalonate pathway inhibitor wouldn't change the pharmacology. It would change the questions we're obligated to ask.